S
Siddappa N. Byrareddy
Researcher at University of Nebraska Medical Center
Publications - 152
Citations - 7188
Siddappa N. Byrareddy is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 22, co-authored 121 publications receiving 4599 citations. Previous affiliations of Siddappa N. Byrareddy include Emory University & Harvard University.
Papers
More filters
Journal ArticleDOI
Early treatment with anti-α4β7 antibody facilitates increased gut macrophage maturity in SIV-infected rhesus macaques
Samuel D. Johnson,Lindsey A. Knight,Narendra Kumar,Omalla A. Olwenyi,Michellie Thurman,Smriti Mehra,Mahesh Mohan,Siddappa N. Byrareddy +7 more
TL;DR: This article showed that anti-α4β7 administered to SIV-infected macaques increases the maturity of macrophage phenotypes typically lost in the small intestines during SIV disease progression.
Journal ArticleDOI
HIV-associated dysbiosis and immune recovery during antiretroviral therapy.
TL;DR: New data demonstrate an interdependence of microbiome and therapy response, and additional studies were urgently required to fully elucidate this crosstalk and microbiome dynamics from before/after infection and finally, long-term viral suppression with cART.
Journal ArticleDOI
Inflammation-Associated Lung Tissue Remodeling and Fibrosis in Morphine-Dependent SIV-Infected Macaques.
Divya T. Chemparathy,Susmita Sil,Shannon Callen,Hitendra S. Chand,Mohan L. Sopori,Todd A. Wyatt,Arpan Acharya,Siddappa N. Byrareddy,Howard S. Fox,Shilpa Buch +9 more
TL;DR: In this paper , the progression of lung tissue remodeling in a morphine (Mor)exposed rhesus macaque model of SIV infection was investigated in archival lung tissues of the SIVmac-251/macaque model with or without Mor dependence.
Posted ContentDOI
Pathways for Dolutegravir Transformation from a Daily Oral to a Once-a-Year Parenteral Medicine
Suyash Deodhar,Brady Sillman,Aditya N. Bade,J. M. McMillan,Nagsen Gautam,B. Hanson,Bhagya Laxmi Dyavar Shetty,Adam M. Szlachetka,Morgan P. Johnston,Michellie Thurman,Daniel J Munt,Alekha K. Dash,Milica Marković,Arik Dahan,Yazen Alnouti,Bhavesh D. Kevadiya,Siddappa N. Byrareddy,Samuel M. Cohen,Benson J Edagwa,Howard E. Gendelman +19 more
TL;DR: The NM2DTG LA product can impact therapeutic adherence, tolerability, and access to a widely used integrase inhibitor in resource-limited and rich settings to reduce HIV-1 transmission and achieve optimal treatment outcomes.